Allianz Asset Management GmbH Has $4.98 Million Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Allianz Asset Management GmbH increased its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 23.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,788 shares of the health services provider's stock after acquiring an additional 10,074 shares during the quarter. Allianz Asset Management GmbH owned about 0.16% of Amedisys worth $4,982,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new position in Amedisys in the 4th quarter valued at $83,061,000. Pentwater Capital Management LP grew its holdings in Amedisys by 178.3% in the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock valued at $107,132,000 after buying an additional 756,000 shares in the last quarter. AQR Arbitrage LLC grew its holdings in Amedisys by 59.1% in the 4th quarter. AQR Arbitrage LLC now owns 471,965 shares of the health services provider's stock valued at $42,812,000 after buying an additional 175,311 shares in the last quarter. Toronto Dominion Bank acquired a new position in Amedisys in the 4th quarter valued at $15,801,000. Finally, CIBRA Capital Ltd grew its holdings in Amedisys by 359.7% in the 1st quarter. CIBRA Capital Ltd now owns 216,775 shares of the health services provider's stock valued at $20,080,000 after buying an additional 169,616 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Trading Down 0.1%

Shares of AMED stock traded down $0.07 during mid-day trading on Friday, reaching $98.53. 300,614 shares of the stock traded hands, compared to its average volume of 362,936. The stock's fifty day simple moving average is $96.65 and its two-hundred day simple moving average is $94.12. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $99.00. The company has a market cap of $3.23 billion, a price-to-earnings ratio of 38.34, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The company has a quick ratio of 1.29, a current ratio of 1.36 and a debt-to-equity ratio of 0.26.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. The firm had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The business's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $0.98 earnings per share. On average, research analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Analyst Ratings Changes

AMED has been the subject of several recent analyst reports. Royal Bank Of Canada restated an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.